BidaskClub upgraded shares of REGENXBIO (NASDAQ:RGNX) from a hold rating to a buy rating in a research note released on Thursday.
A number of other brokerages have also issued reports on RGNX. Zacks Investment Research upgraded REGENXBIO from a hold rating to a buy rating and set a $23.00 price target for the company in a report on Saturday, August 12th. Evercore ISI initiated coverage on REGENXBIO in a report on Wednesday, August 16th. They issued an outperform rating and a $25.00 price target for the company. Morgan Stanley reiterated an overweight rating and issued a $34.00 price target on shares of REGENXBIO in a report on Thursday, November 9th. Bank of America boosted their price objective on shares of REGENXBIO from $29.00 to $33.00 and gave the stock a buy rating in a research note on Thursday, September 21st. Finally, Chardan Capital boosted their price objective on shares of REGENXBIO from $50.00 to $55.00 and gave the stock a buy rating in a research note on Wednesday, August 9th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the company. The company presently has an average rating of Buy and an average price target of $42.43.
Shares of REGENXBIO (NASDAQ:RGNX) traded up $1.45 during midday trading on Thursday, hitting $31.75. The company had a trading volume of 325,795 shares, compared to its average volume of 278,419. REGENXBIO has a 12-month low of $16.30 and a 12-month high of $36.10.
REGENXBIO (NASDAQ:RGNX) last announced its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.67) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.04. The firm had revenue of $1.34 million during the quarter. REGENXBIO had a negative return on equity of 39.33% and a negative net margin of 764.06%. research analysts expect that REGENXBIO will post -2.71 EPS for the current fiscal year.
In related news, CFO Vittal Vasista sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, September 15th. The shares were sold at an average price of $27.39, for a total value of $136,950.00. Following the completion of the transaction, the chief financial officer now owns 99,594 shares of the company’s stock, valued at $2,727,879.66. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Donald J. Hayden, Jr. sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 11th. The stock was sold at an average price of $34.95, for a total transaction of $699,000.00. The disclosure for this sale can be found here. Insiders sold 122,110 shares of company stock valued at $3,757,720 in the last three months. 17.00% of the stock is currently owned by insiders.
A number of large investors have recently modified their holdings of the stock. Pura Vida Investments LLC raised its stake in REGENXBIO by 17.7% in the third quarter. Pura Vida Investments LLC now owns 33,920 shares of the biotechnology company’s stock worth $1,118,000 after buying an additional 5,100 shares in the last quarter. Perceptive Advisors LLC increased its position in shares of REGENXBIO by 5.1% during the third quarter. Perceptive Advisors LLC now owns 1,441,186 shares of the biotechnology company’s stock worth $47,487,000 after purchasing an additional 70,000 shares in the last quarter. Jane Street Group LLC acquired a new position in shares of REGENXBIO during the third quarter worth $476,000. RTW Investments LP increased its position in shares of REGENXBIO by 20.9% during the third quarter. RTW Investments LP now owns 1,539,005 shares of the biotechnology company’s stock worth $50,710,000 after purchasing an additional 266,235 shares in the last quarter. Finally, Schwab Charles Investment Management Inc. increased its position in shares of REGENXBIO by 25.4% during the third quarter. Schwab Charles Investment Management Inc. now owns 122,509 shares of the biotechnology company’s stock worth $4,037,000 after purchasing an additional 24,814 shares in the last quarter. 68.73% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: This piece was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another site, it was illegally stolen and republished in violation of international copyright laws. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2017/12/08/regenxbio-rgnx-upgraded-to-buy-by-bidaskclub.html.
REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.
Receive News & Ratings for REGENXBIO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for REGENXBIO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.